The therapeutic potential of cannabis and cannabinoids for treating schizophrenia, nausea, pain, insomnia, anxiety, et al. is increasingly purported. Yet, there’s still not enough science to know all the potential benefits of cannabinoids or what they do to the human body and brain, which is, at least in part, because smoked cannabis is not well-suited to scientific evaluation. Individual molecules like cannabidiol (CBD), on the other hand, have already shown efficacy for treating seizures and are of interest not only to scientists but also to the FDA, CDC, SAMHSA, NIDA, and other federal partners. The goal of our group is to discuss and pursue the development of cannabinoids [e.g., CBD and ∆9-tetrahydrocannabinol (THC)], from preclinical leads to first-in-class medications, for treating various conditions.